Inhibiting RRM2 to enhance the anticancer activity of chemotherapy

被引:95
作者
Zhan, Yaqiong [1 ]
Jiang, Lushun [1 ]
Jin, Xuehang [1 ]
Ying, Shuaibing [1 ]
Wu, Zhe [1 ]
Wang, Li [2 ]
Yu, Wei [1 ]
Tong, Jiepeng [1 ]
Zhang, Li [1 ]
Lou, Yan [1 ]
Qiu, Yunqing [1 ]
机构
[1] Zhejiang Univ, Coll Med,State Key Lab Diag & Treatment Infect Di, Affiliated Hosp 1,Collaborat Innovat Ctr Diag & T, Natl Clin Res Ctr Infect Dis,Zhejiang Prov Key La, 79 QingChun Rd, Hangzhou 310000, Zhejiang, Peoples R China
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Rehabil Med, 79 QingChun Rd, Hangzhou 310000, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
Ribonucleotide reductase subunit M2; Chemotherapy; Chemoresistance; Small interfering RNA; RRM2; inhibitors; Kinase inhibitors; RIBONUCLEOTIDE REDUCTASE M2; 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE 3-AP; ANTISENSE OLIGONUCLEOTIDE GTI-2040; MESSENGER-RNA EXPRESSION; BREAST-CANCER CELLS; PHASE-I TRIAL; NF-KAPPA-B; PANCREATIC-CANCER; DNA-DAMAGE; SUBUNIT M2;
D O I
10.1016/j.biopha.2020.110996
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
RRM2, the small subunit of ribonucleotide reductase, is identified as a tumor promotor and therapeutic target. It is common to see the overexpression of RRM2 in chemo-resistant cancer cells and patients. RRM2 mediates the resistance of many chemotherapeutic drugs and could become the predictor for chemosensitivity and prognosis. Therefore, inhibition of RRM2 may be an effective means to enhance the anticancer activity of chemotherapy. This review tries to discuss the mechanisms of RRM2 overexpression and the role of RRM2 in resistance to chemotherapy. Additionally, we compile the studies on small interfering RNA targets RRM2, RRM2 inhibitors, kinase inhibitors, and other ways that could overcome the resistance of chemotherapy or exert synergistic anticancer activity with chemotherapy through the expression inhibition or the enzyme inactivation of RRM2.
引用
收藏
页数:8
相关论文
共 97 条
[61]   Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells [J].
Pontarin, Giovanna ;
Ferraro, Paola ;
Bee, Leonardo ;
Reichard, Peter ;
Bianchi, Vera .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (33) :13302-13307
[62]   Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance [J].
Putluri, Nagireddy ;
Maity, Suman ;
Kommangani, Ramakrishna ;
Creighton, Chad J. ;
Putluri, Vasanta ;
Chen, Fengju ;
Nanda, Sarmishta ;
Bhowmik, Salil Kumar ;
Terunuma, Atsushi ;
Dorsey, Tiffany ;
Nardone, Agostina ;
Fu, Xiaoyong ;
Shaw, Chad ;
Sarkar, Tapasree Roy ;
Schiff, Rachel ;
Lydon, John P. ;
O'Malley, Bert W. ;
Ambs, Stefan ;
Das, Gokul M. ;
Michailidis, George ;
Sreekumar, Arun .
NEOPLASIA, 2014, 16 (05) :390-402
[63]   Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis [J].
Qi, Wenxiu ;
Xu, Xiaohao ;
Wang, Manying ;
Li, Xiangyan ;
Wang, Chaonan ;
Sun, Liping ;
Zhao, Daqing ;
Sun, Liwei .
BIOCHEMICAL PHARMACOLOGY, 2019, 164 :273-282
[64]   Identification of lncRNA NEAT1/miR-21/RRM2 axis as a novel biomarker in breast cancer [J].
Quan, Dongling ;
Chen, Kai ;
Zhang, Jingru ;
Guan, Yiqing ;
Yang, Danni ;
Wu, Huanxian ;
Wu, Shaoyu ;
Lv, Lin .
JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (04) :3372-3381
[65]   The current state and future directions of RNAi-based therapeutics [J].
Setten, Ryan L. ;
Rossi, John J. ;
Han, Si-ping .
NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (06) :421-446
[66]   Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer [J].
Shah, Khyati N. ;
Wilson, Elizabeth A. ;
Malla, Ritu ;
Elford, Howard L. ;
Faridi, Jesika S. .
MOLECULAR CANCER THERAPEUTICS, 2015, 14 (11) :2411-2421
[67]   AKT-Induced Tamoxifen Resistance Is Overturned by RRM2 Inhibition [J].
Shah, Khyati N. ;
Mehta, Kshama R. ;
Peterson, David ;
Evangelista, Marie ;
Livesey, John C. ;
Faridi, Jesika S. .
MOLECULAR CANCER RESEARCH, 2014, 12 (03) :394-407
[68]   Ribonucleotide reductase inhibitors and future drug design [J].
Shao, J. ;
Zhou, B. ;
Chu, Bernard ;
Yen, Y. .
CURRENT CANCER DRUG TARGETS, 2006, 6 (05) :409-431
[69]   Targeting ribonucleotide reductase for cancer therapy [J].
Shao, Jimin ;
Liu, Xiyong ;
Zhu, Lijun ;
Yen, Yun .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (12) :1423-1437
[70]  
Shinoda Shuhei, 2018, Oncotarget, V9, P28434, DOI 10.18632/oncotarget.25421